---
title: "Tremfya (guselkumab), all indications: Specific populations questions"
description: "Specific populations questions on Tremfya (guselkumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Is Tremfya safe during pregnancy? Can you breastfeed while taking Tremfya? Is Tremfya dosing different for older adults? Does Tremfya need dose adjustment for kidney or liver impairment? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/tremfya/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab), all indications: Specific populations questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)

## Pregnancy and breastfeeding

<a id="tremfya-pregnancy"></a>

### Is Tremfya safe during pregnancy?

> “Pregnancy Exposure Registry
> There is a pregnancy registry that monitors pregnancy outcomes in women 
> exposed to TREMFYA during pregnancy. Patients should be encouraged 
> to enroll in the registry by visiting www.mothertobaby.org/ongoing-study/ 
> tremfya-guselkumab, by calling 1-877-311-8972, or emailing MotherToBaby@
> health.ucsd.edu.”

Source: [TREMFYA: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=5)

> “Available data from literature, post-marketing reports, and ongoing pregnancy 
> registry with TREMFYA use in pregnant women are insufficient to establish a 
> drug-associated risk of major birth defects, miscarriage or other adverse maternal 
> or fetal outcomes. Monoclonal antibodies are actively transported across the 
> placenta (see Clinical Considerations).”

Source: [TREMFYA: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=5)

> “Transport of endogenous IgG antibodies across the placenta increases as 
> pregnancy progresses and peaks during the third trimester. Therefore, TREMFYA 
> may be present in infants exposed in utero. The potential clinical impact of 
> guselkumab exposure in infants exposed in utero should be considered.”

Source: [TREMFYA: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=5)

<a id="tremfya-breastfeeding"></a>

### Can you breastfeed while taking Tremfya?

> “There are no data on the presence of guselkumab in human milk, the effects 
> on the breastfed infant, or the effects on milk production. Guselkumab was not 
> detected in the milk of lactating cynomolgus monkeys. Endogenous maternal IgG 
> and monoclonal antibodies are transferred into human milk. The effects of local 
> gastrointestinal exposure and the extent of systemic exposure in the breastfed 
> infant to guselkumab are unknown. The developmental and health benefits of 
> breastfeeding should be considered along with the mother's clinical need for 
> TREMFYA and any potential adverse effects on the breastfed infant from TREMFYA 
> or from the underlying maternal condition.”

Source: [TREMFYA: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=5)

## Specific populations

<a id="tremfya-older-adults"></a>

### Is Tremfya dosing different for older adults?

> “Of the 6418 subjects with plaque psoriasis, psoriatic arthritis, ulcerative colitis, or 
> Crohn’s disease exposed to TREMFYA, a total of 489 subjects were 65 years or 
> older, and 55 subjects were 75 years or older. Clinical studies of TREMFYA, within 
> each indication, did not include sufficient numbers of subjects 65 years of age and 
> older to determine whether they respond differently from younger adult subjects. 
> No clinically meaningful differences in the pharmacokinetics of guselkumab were 
> observed based on age [see Clinical Pharmacology (12.3)].”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

> “No apparent differences in clearance were observed in subjects ≥ 65 years of 
> age compared to subjects < 65 years of age, suggesting no dose adjustment is 
> needed for elderly subjects.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

<a id="tremfya-kidney-liver-impairment"></a>

### Does Tremfya need dose adjustment for kidney or liver impairment?

> “No specific trials have 
> been conducted to determine the effect of renal or hepatic impairment on the 
> pharmacokinetics of guselkumab.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

## Related pages
- [Medical information: Tremfya (guselkumab): All indications](https://www.evicenter.com/medical-information/tremfya)
- [Indication](https://www.evicenter.com/medical-information/tremfya/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/tremfya/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/tremfya/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/tremfya/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya/access-and-coverage)
